Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

Abstract

Single-agent TLC D-99 produces less cardiotoxicity than doxorubicin, while providing comparable antitumor activity.